17
edits
Changes
mLine 1:
Line 1: − {{DISPLAYTITLE:Follicular lymphoma}} − + − + + + + Line 17:
Line 19: − + + + + + + + Line 66:
Line 74: − {| class="wikitable" − |'''Signs and Symptoms''' − |EXAMPLE Asymptomatic (incidental finding on complete blood counts) − EXAMPLE B-symptoms (weight loss, fever, night sweats)+ − + − EXAMPLE Fatigue+ − + − EXAMPLE Lymphadenopathy (uncommon)+ − |- − |'''Laboratory Findings''' − |EXAMPLE Cytopenias − − EXAMPLE Lymphocytosis (low level) − |} − + − *FL commonly presents as painless lymphadenopathy<ref name=":1" /> − *May wax and wane over years before diagnosis − *Majority of cases have widespread involvement at diagnosis<ref name=":1" /> − *Bone marrow involvement in 40-70% of cases at diagnosis − *May not require treatment depending staging and other parameters. − + Line 101:
Line 95: − + Line 109:
Line 103: − + − + Line 120:
Line 114: − <blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote> − Typical FL has CD10+, BL2+. Atypical FL subgroups CD10- and/or BCL2 - all FL are STMN+ - useful differentiator between atypical FL and MZL [9]+ Line 140:
Line 133: − <blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 9, 10]</blockquote> − Put your text here and fill in the table+ Line 153:
Line 145: − + − EXAMPLE 30% (add reference)+ − + − + − |EXAMPLE − − The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). − + Line 181:
Line 170: − + − + Line 196:
Line 185: − + Line 243:
Line 232: − + Line 270:
Line 259: − + Line 276:
Line 265: − + − + Line 312:
Line 301: − + Line 384:
Line 373: − + Line 398:
Line 387: − Progenetix.org Follicular Lymphoma CNV plot: <nowiki>https://progenetix.org/subsets/list?filters=NCIT:C3209&datasetIds=progenetix</nowiki> − − + − + − + − − [Https://progenetix.org/subsets/list%3Ffilters%3DNCIT:C3209%26datasetIds%3Dprogenetix Progenetix.org Follicular Lymphoma CNV plot] your links here (use "Link" icon at top of page) − '''+ Line 421:
Line 406: − + + +
→Chromosomal Rearrangements (Gene Fusions)
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
{{Under Construction}}
{{Under Construction}}
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Follicular Lymphoma]].
<blockquote class="blockedit">{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Follicular Lymphoma]].
Other relevent pages include: [[Testicular Follicular Lymphoma]]
Other relevent pages include: [[HAEM4:Testicular Follicular Lymphoma]]
Note: autho needs to correlate with Testicular Follicular Lymphoma
Note: autho needs to correlate with Testicular Follicular Lymphoma
}}</blockquote>
}}</blockquote>
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
==Primary Author(s)*==
==Primary Author(s)*==
__TOC__
__TOC__
==Cancer Category/Type==
==Cancer Category / Type==
Mature B Cell Neoplasm
Mature B Cell Neoplasm
==Cancer Sub-Classification / Subtype==
==Cancer Sub-Classification / Subtype==
''In situ'' FL,
Duodenal-type FL,
Pediatric FL,
Follicular Lymphoma
Follicular Lymphoma
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
*FL commonly presents as painless lymphadenopathy<ref name=":12" />
*May wax and wane over years before diagnosis
*Majority of cases have widespread involvement at diagnosis<ref name=":12" />
*Bone marrow involvement in 40-70% of cases at diagnosis
*May not require treatment depending staging and other parameters.
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
<blockquote class="blockedit">{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
</blockquote>
</blockquote>
==Sites of Involvement==
==Sites of Involvement==
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
==Morphologic Features==
==Morphologic Features==
Consists of both centrocytes and centroblasts, with the relative proportions of these cells informing grading
Consists of both centrocytes and centroblasts, with the relative proportions of these cells informing grading
Grade I: 0-5 centroblasts/high power field (hpf)
Grade 1: 0-5 centroblasts/high power field (hpf)
Grade II: 6-15 centroblasts/hpf
Grade 2: 6-15 centroblasts/hpf
Grade III: >15 centroblasts/hpf
Grade III: >15 centroblasts/hpf
==Immunophenotype==
==Immunophenotype==
Typically, FL is CD10+, BL2+. Atypical FL subgroups CD10- and/or BCL2 - all FL are STMN+ - useful differentiator between atypical FL and MZL [9]
{| class="wikitable sortable"
{| class="wikitable sortable"
==Chromosomal Rearrangements (Gene Fusions)==
==Chromosomal Rearrangements (Gene Fusions)==
<br />
{| class="wikitable sortable"
{| class="wikitable sortable"
!Notes
!Notes
|-
|-
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
|t(14;18)(q32;q21)||5' IGH / 3' BCL2||der(18)||80%~90%
|No
|Yes
|No
|No
|No
|Yes
|Rarely, BCL2 rearrangement may also be observed with IGK at 2p11.2 or IGL at 22q11.22. Additional info and example karyotypes can be found here.
|}
|}
<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
<blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 5, 7, 9, 11]</blockquote>
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 5, 7, 9, 11]</blockquote>
</blockquote>
</blockquote>
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
<blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
* Chromosomal Rearrangements (Gene Fusions)
* Chromosomal Rearrangements (Gene Fusions)
* Individual Region Genomic Gain/Loss/LOH
* Individual Region Genomic Gain/Loss/LOH
</blockquote>
</blockquote>
==Individual Region Genomic Gain/Loss/LOH==
==Individual Region Genomic Gain / Loss / LOH==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
|}
|}
<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}
<blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}
deletions in 1p36, 6q, 10q, 13p, 17p; gains of 1q, 2p, 7, 8, 12q, 18q
deletions in 1p36, 6q, 10q, 13p, 17p; gains of 1q, 2p, 7, 8, 12q, 18q
|}
|}
<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
<blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[11]</blockquote>
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[11]</blockquote>
</blockquote>
</blockquote>
==Gene Mutations (SNV/INDEL)==
==Gene Mutations (SNV / INDEL)==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}
<blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}
Put your text here and/or fill in the tables
Put your text here and/or fill in the tables
|}
|}
<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
<blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
''BCR-NFκB'', ''JAK/STAT''; ''mTORC'' signaling
''BCR-NFκB'', ''JAK/STAT''; ''mTORC'' signaling
==Additional Information==
==Additional Information==
Precursor B cells typically mature in the marrow, where they may become mature naïve B cells or may apoptose. Following antigen exposure, mature B cells may become short lived plasma cells, or may enter the germinal center and undergo somatic hypermutation and heavy chain class switching.
Precursor B cells typically mature in the marrow, where they may become mature naïve B cells or may apoptose. Following antigen exposure, mature B cells may become short lived plasma cells, or may enter the germinal center and undergo somatic hypermutation and heavy chain class switching.
==Links==
==Links==
[[Testicular Follicular Lymphoma]]
[[HAEM5:Follicular lymphoma]]
[[In Situ Follicular Neoplasia]]
[[HAEM5:In situ follicular B-cell neoplasm]]
[[Duodenal-Type Follicular Lymphoma]]
[[HAEM5:Duodenal-type follicular lymphoma]]
==References==
==References==
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
<br />
==Notes==
==Notes==
<nowiki>*</nowiki>''Citation of this Page'': “Follicular lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Follicular_lymphoma</nowiki>.
<nowiki>*</nowiki>''Citation of this Page'': “Follicular lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Follicular_lymphoma</nowiki>.
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases F]]
[[Category:HAEM5]]
[[Category:DISEASE]]
[[Category:Diseases F]]